Amgen stock was dropping in premarket trading after releasing data from a Phase 2 study for its experimental weight-loss drug ...

Alumis is advancing ESK-001 for plaque psoriasis with phase 3 data expected in 2026. Read why ALMS stock is compelling yet ...

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

Once a controversial European depression treatment that never made it to the U.S. | The treatment, which was once a Pfizer ...

Bayer now says it expects to make €3 billion in sales for its prostate cancer treatment Nubeqa, up from an earlier estimate of €1 billion, after reviewing new data for the drug in metastatic ...

Merck & Co’s immuno-oncology drug ... market approvals for over 20 oncology indications in the US, and is continuing to expand into new indications and markets globally.” Strong 2018 sales ...

The biotech industry has been described as the Wild West of the stock market. While that level of success is only obvious in ...

Verona's approval of ensifentrine in COPD offers promising potential with its MoA and safety profile in a competitive market.

Eli Lilly reported total tirzepatide sales that rocketed 272% year over year to $11 billion during the first nine months of ...

Investors are assessing the likelihood Trump will deliver on his threat to impose fresh tariffs on China, Canada and Mexico.